Jaffer A. Ajani - Researcher Profile

Publications

3 shown

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more

2021 The Lancet 2580 citations

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly , Jaffer A. Ajani , Jarosław Kużdżał +24 more

Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among ...

2021 New England Journal of Medicine 1584 citations

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani , Thomas A. D’Amico , David J. Bentrem +38 more

Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic l...

2022 Journal of the National Comprehensive... 1529 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 5,693
Institution: The University of Texas MD Anderson Cancer Center

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-9946-0629

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.